Claritas HealthTech has received clearance from India’s regulatory authority for medical devices, the Central Drugs Standard Control Organisation (CDSCO), for importing and marketing the Claritas iPET software in India.
Claritas iPET is designed for accelerated and reduced isotope scans. It received the US Food and Drug Administration (FDA) clearance in January 2022.
It uses an algorithm-based solution to improve the quality and efficiency of PET and SPECT scans by denoising, sharpening organ boundaries, and achieving super-resolution.
Additionally, it improves scans further by overlaying MRI or CT images of the same region to provide additional details.
The enhancement capabilities of Claritas iPET can also be used to lower scan times and required isotope dosage, while still producing diagnostic quality images.
Claritas HealthTech India managing director Nischay Saraf said: “We have been working with clinicians anticipating the clearance and approvals of Claritas iPET for the Indian market, and will be deploying the platform nationwide, both in the private and public healthcare sectors.
“With over 500,000 PET scans a year in India, our aim is to assist the clinicians with diagnostic accuracy and workflow improvement.”
Claritas iPET is compatible with all radionuclides and integrates easily into existing systems, Claritas HealthTech claimed.
The capability allows hospitals and imaging centres to enhance images from accelerated scans, thereby increasing scan throughput and profitability.
Additionally, these enhancements contribute to a significantly improved patient experience.
Claritas iPET is compatible across various manufacturer types and equipment brands.
Furthermore, it can be integrated onsite or accessed conveniently via the cloud.
Claritas HealthTech UK managing director Chetan Baxi said: “Being able to bring Claritas iPET to market in India marks a significant milestone for us.
“Along with China and Brazil where we are awaiting our regulatory clearances, India has been a top priority for us. We have seen a very strong demand for our solutions in India, as such, we will continue to add several product and service offerings by Q4 2024.”
Claritas HealthTech focuses on researching image enhancement, machine vision, and artificial intelligence (AI), specifically in medical image processing and diagnostic interpretation.
The company develops advanced software products to empower doctors in making accurate diagnoses and enhance patient outcomes.
